{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["49(2)"],"submitter":["Marrano N"],"funding":["Università degli Studi di Bari Aldo Moro"],"pubmed_abstract":["<h4>Purpose</h4>First-line treatment for renal cell carcinoma (RCC) commonly includes immune checkpoint inhibitors (ICIs), either as monotherapy or in combination with anti-angiogenic agents. These therapies can lead to endocrine immune-related adverse events (irAEs). This study aimed to identify predictive risk factors for the development of endocrine irAEs associated with ICI-based therapies.<h4>Methods</h4>We conducted an observational, retrospective, single-center study involving 72 patients with RCC who initiated first-line treatment with ICIs (either in combination with another ICI or an anti-angiogenic agent) between January 2018 and May 2023. All patients had at least 18 months of clinical and biochemical follow-up.<h4>Results</h4>51.39% of patients experienced endocrine irAEs, inc"],"journal":["Journal of endocrinological investigation"],"pagination":["399-412"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12924852"],"repository":["biostudies-literature"],"pubmed_title":["Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors."],"pmcid":["PMC12924852"],"pubmed_authors":["Perrini S","Ganini C","Caporusso M","Cignarelli A","Laviola L","Giorgino F","Porta C","Marrano N","Natalicchio A","Borraccino A"],"additional_accession":[]},"is_claimable":false,"name":"Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors.","description":"<h4>Purpose</h4>First-line treatment for renal cell carcinoma (RCC) commonly includes immune checkpoint inhibitors (ICIs), either as monotherapy or in combination with anti-angiogenic agents. These therapies can lead to endocrine immune-related adverse events (irAEs). This study aimed to identify predictive risk factors for the development of endocrine irAEs associated with ICI-based therapies.<h4>Methods</h4>We conducted an observational, retrospective, single-center study involving 72 patients with RCC who initiated first-line treatment with ICIs (either in combination with another ICI or an anti-angiogenic agent) between January 2018 and May 2023. All patients had at least 18 months of clinical and biochemical follow-up.<h4>Results</h4>51.39% of patients experienced endocrine irAEs, inc","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T15:09:08.47Z","creation":"2026-07-09T11:02:59.569Z"},"accession":"S-EPMC12924852","cross_references":{"pubmed":["41212411"],"doi":["10.1007/s40618-025-02732-z"]}}